Anti-NY-ESO-1 murine TCR transduced autologous peripheral blood lymphocytes (Albert Einstein College of Medicine/NCI)

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameAnti-NY-ESO-1 murine TCR transduced autologous peripheral blood lymphocytes (Albert Einstein College of Medicine/NCI)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > TCR therapy
Mechanisms of ActionAnti-NY-ESO-1
TargetsCancer/testis antigen 1
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesAlbert Einstein College Of Medicine IncNational Cancer Institute
China Registration ClassN/A

Develop Information

Active CompaniesNational Cancer InstituteAlbert Einstein College Of Medicine Inc
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A